ReviewTranslational lung cancer research2025
Advances in the research of leptomeningeal metastases in non-small cell lung cancer: a narrative review.
Review in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Corticosteroid-induced severe psychiatric manifestations in a patient with leptomeningeal metastases from lung adenocarcinoma.Frontiers in pharmacology · 2026Article
- A survival prediction model for leptomeningeal metastasis patients with non-small cell lung cancer based on deep learning.BMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Lung cancer is among the malignant tumors with the highest morbidity and mortality rates, with approximately 80-85% of cases being non-small cell lung cancer (NSCLC). The incidence of central nervous system metastases is notably high, and about 3-5% of NSCLC patients develop leptomeningeal metastases. As the survival rates for NSCLC patients improve, the incidence of leptomeningeal metastases (LMs) continues to rise. This article reviews the mechanisms of leptomeningeal metastases, diagnostic and therapeutic achievements, and ongoing challenges, providing insight into the diagnosis and management of NSCLC with LM and the development of related clinical strategies. Methods: We searched PubMed, MEDLINE, EMBASE, Cochrane Library, and major international conferences for all types of articles published in English up to December 31, 2024. Key Content and Findings: Patients with LM face significant challenges in diagnosis and treatment due to the low sensitivity of current diagnostic methods, the nonspecific nature of clinical symptoms, and the unique anatomical location of the leptomeninges. While recent exploratory studies have identified sensitive molecular markers and potential therapeutic strategies, large-scale prospective studies are still needed for validation. Conclusions: In conclusion, a multidisciplinary approach with individualized treatment plans is essential for LM patients. For LM patients with driver gene-positive, targeted therapy is the mainstay, supplemented by local therapy or anti-angiogenic agents. For LM patients with driver gene-negative, chemotherapy combined with immunotherapy is the mainstay. If treatment is not effective, means such as sequential therapy and higher drug doses provide new treatment ideas and options for LM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.